Latest Ai Platforms News

Nexion Group has finalized the sale of its Nexion Networks and Blue Sky Telecom subsidiaries, pivoting its focus towards AI-driven business intelligence through Fuse Forward.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Activeport Group Ltd has launched a new AI model routing platform that leverages its GPU orchestration expertise to deliver secure, sovereign AI hosting with hybrid cloud compatibility.

Artrya Limited has expanded its SAPPHIRE clinical study with Ascension, one of the largest US non-profit health systems, joining as the fourth major participant. This move strengthens the study’s reach and advances the evaluation of Artrya’s AI-powered Salix platform for coronary artery disease detection.

Xero Limited reports a robust 20% revenue increase in H1 FY26, driven by strong subscriber growth and the strategic Melio acquisition. The company’s innovative AI platform and improved profitability underscore its confident path toward accelerated US market expansion.

BrainChip Holdings Ltd has launched a fully underwritten $35 million placement alongside a $2 million share purchase plan to fund the commercialization of its Akida 2.0 technology and new TENNs product development. The capital raise underscores the company’s commitment to expanding its footprint in the rapidly growing edge AI market.

BrainChip Holdings Ltd has secured A$35 million through a fully underwritten placement and an additional A$2 million via a Share Purchase Plan to fast-track its neuromorphic AI technology and product development.

Algorae Pharmaceuticals has launched AlgoraeOS Version 2, a major AI platform upgrade that surpasses leading models including those from Google DeepMind, promising to accelerate drug-combination discovery.

Artrya secures participation from Mass General Brigham, a leading U.S. cardiovascular research center, in its pivotal SAPPHIRE Study launching in early 2026. This collaboration aims to validate Artrya’s AI-powered Salix platform for earlier and more effective coronary artery disease detection.

Vection Technologies reports a 60% surge in operating cash flow in Q1 FY26, driven by a landmark $22.3 million Defence framework agreement and a strategic $21 million capital raise. The company is poised for sustainable profitability with a record $75 million contract pipeline through 2028.

Artrya Limited has completed the second tranche of its share placement, raising $14.7 million to advance its AI-powered Salix platform for coronary artery disease detection.